FY2021 · ended Dec 31, 2021 · Revenue $0 · Filed Mar 31, 2023
Inhibitor Therapeutics, Inc. (INTI) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $515,758 in cash and investments and $21,566 in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-287,730
+10.3% vs year-ago TTM
Operating cash flow (TTM)
$-3.22M
+4.1% vs year-ago TTM
Free cash flow
—
EPS
$-0.02
+0.0% vs prior year
Dividend per share
None
Shares outstanding
172.57M
+0.1% vs prior year
Net cash
$494,192
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INTI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1042418
- Former names
- HedgePath Pharmaceuticals, Inc. (until Aug 12, 2019); COMMONWEALTH BIOTECHNOLOGIES INC (until May 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$3.4M | -$3.7M | -$3.4M | -$657,926 | -$325,395 |
| Net income | -$3.3M | -$3.3M | -$3.0M | $12.1M | -$298,632 |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | $0.03 | — |
| Operating cash flow | -$3.2M | -$3.2M | -$2.7M | $11.7M | -$220,433 |
| Total assets | $2.5M | $5.7M | $8.9M | $12.0M | $58,784 |
| Total liabilities | $3.8M | $3.7M | $3.7M | $3.7M | $3.7M |
| Stockholders' equity | -$1.3M | $2.0M | $5.3M | $8.3M | -$3.6M |
| Cash and investments | $2.4M | $5.6M | $8.8M | $12.0M | $30,626 |
| Total debt | $98,502 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 18, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 1, 2026 | Apr 1, 2026 |
| 8-K |
Current report
Other events
|
Apr 1, 2026 | Apr 1, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
All 724 Inhibitor Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.